1580 related articles for article (PubMed ID: 17334511)
41. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis.
Lei X; Reheman A; Hou Y; Zhou H; Wang Y; Marshall AH; Liang C; Dai X; Li BX; Vanhoorelbeke K; Ni H
Thromb Haemost; 2014 Feb; 111(2):279-89. PubMed ID: 24172860
[TBL] [Abstract][Full Text] [Related]
42. Anti-glycoprotein Ib causes platelet aggregation: different effects of blocking glycoprotein Ib and glycoprotein IIb/IIIa in the high shear filterometer.
O'Brien JR; Etherington MD
Blood Coagul Fibrinolysis; 1998 Sep; 9(6):453-61. PubMed ID: 9818994
[TBL] [Abstract][Full Text] [Related]
43. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
[TBL] [Abstract][Full Text] [Related]
44. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
45. Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.
Johnson FL; Boyer JL; Leese PT; Crean C; Krishnamoorthy R; Durham T; Fox AW; Kellerman DJ
Platelets; 2007 Aug; 18(5):346-56. PubMed ID: 17654304
[TBL] [Abstract][Full Text] [Related]
46. A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist.
Wang WJ; Huang TF
Thromb Haemost; 2001 Oct; 86(4):1077-86. PubMed ID: 11686327
[TBL] [Abstract][Full Text] [Related]
47. Cangrelor attenuates coated-platelet formation.
Norgard NB; Hann CL; Dale GL
Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
49. Delayed inhibition of agonist-induced granulocyte-platelet aggregation after low-dose sevoflurane inhalation in humans.
Wacker J; Lucchinetti E; Jamnicki M; Aguirre J; Härter L; Keel M; Zaugg M
Anesth Analg; 2008 Jun; 106(6):1749-58. PubMed ID: 18499605
[TBL] [Abstract][Full Text] [Related]
50. A novel monoclonal antibody against the extracellular domain of GPIbbeta modulates vWF mediated platelet adhesion.
Perrault C; Moog S; Rubinstein E; Santer M; Baas MJ; de la Salle C; Ravanat C; Dambach J; Freund M; Santoso S; Cazenave JP; Lanza F
Thromb Haemost; 2001 Nov; 86(5):1238-48. PubMed ID: 11816713
[TBL] [Abstract][Full Text] [Related]
51. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.
van Gestel MA; Heemskerk JW; Slaaf DW; Heijnen VV; Reneman RS; oude Egbrink MG
Arterioscler Thromb Vasc Biol; 2003 Mar; 23(3):518-23. PubMed ID: 12615691
[TBL] [Abstract][Full Text] [Related]
52. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
53. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
54. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
55. [Erythrocytes modulate the anti-aggregation effect of aspirin and dipyridamole. Study under static conditions and in a flow system].
Bozzo J; Hernández MR; Ordinas A
Sangre (Barc); 1996 Feb; 41(1):13-8. PubMed ID: 8779028
[TBL] [Abstract][Full Text] [Related]
56. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
van Giezen JJ; Humphries RG
Semin Thromb Hemost; 2005 Apr; 31(2):195-204. PubMed ID: 15852223
[TBL] [Abstract][Full Text] [Related]
57. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow.
Turner NA; Moake JL; McIntire LV
Blood; 2001 Dec; 98(12):3340-5. PubMed ID: 11719372
[TBL] [Abstract][Full Text] [Related]
58. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Raju NC; Eikelboom JW; Hirsh J
Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
[TBL] [Abstract][Full Text] [Related]
59. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
[TBL] [Abstract][Full Text] [Related]
60. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Leon C; Ravanat C; Freund M; Cazenave JP; Gachet C
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1941-7. PubMed ID: 12933533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
